The global theranostics market, which was valued at USD 1,212.39 million in 2022, is poised for substantial growth and is projected to reach approximately USD 2.36 billion by 2030. This market is expected to grow at a compound annual growth rate (CAGR) of 10.01% from 2023 to 2030, driven by increasing demand for personalized medicine, advancements in molecular imaging, and the rising prevalence of cancer and chronic diseases.
Theranostics β the combination of therapeutics and diagnostics β represents a revolutionary approach in modern medicine. This integrated strategy enables healthcare professionals to tailor treatments to individual patients based on diagnostic test results, significantly enhancing treatment efficacy and minimizing side effects. The convergence of targeted therapy and companion diagnostics is playing a vital role in advancing precision medicine across oncology, neurology, and cardiovascular care.
Market Overview
Theranostics is rapidly transforming the way complex diseases are diagnosed and treated. Unlike traditional “one-size-fits-all” treatment protocols, theranostics integrates diagnostic imaging and targeted therapy into a single, seamless approach. Through the use of biomarkers and companion diagnostics, clinicians can identify specific disease characteristics, predict therapeutic response, and monitor treatment progress.
The rise in cancer incidence worldwide is a primary factor fueling market growth. Oncology is the leading application area for theranostics, particularly in nuclear medicine and radiopharmaceuticals, where radiolabeled drugs are used both for imaging and treatment. The ability to simultaneously diagnose and treat tumors with high specificity makes theranostics a game-changer in cancer care.
Moreover, the growth of molecular imaging technologies, increased investment in R&D by pharmaceutical companies, and regulatory encouragement for personalized therapeutics are further accelerating market expansion. Technological advancements in nanomedicine, biomarkers, and companion diagnostics are opening new frontiers for therapeutic precision.
ππ±π©π₯π¨π«π ππ‘π ππ¨π¦π©π₯πππ ππ¨π¦π©π«ππ‘ππ§π¬π’π―π πππ©π¨π«π πππ«π:
Market Segmentation
The global theranostics market is segmented based on product type, application, and end user.
By Product Type
- Therapeutic Agents
- Include radiopharmaceuticals, targeted drugs, and biologics.
- Designed for use with companion diagnostics to deliver precise therapy.
- Diagnostic Imaging Techniques
- Includes PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), CT (Computed Tomography), and MRI (Magnetic Resonance Imaging).
- Crucial for detecting molecular and functional changes in tissues before structural changes occur.
- Companion Diagnostics
- In-vitro tests or imaging biomarkers used to determine the suitability of a specific therapeutic product.
- Integral to the approval and clinical use of many new targeted drugs.
- Radiopharmaceuticals
- Dual-use agents for both diagnostic imaging and therapy, especially in oncology.
- Include isotopes like Lutetium-177, Gallium-68, and Iodine-131.
By Application
- Oncology
- The largest and fastest-growing segment.
- Theranostics is widely used in prostate cancer, breast cancer, thyroid cancer, and neuroendocrine tumors.
- Radioligand therapy and imaging are setting new standards in cancer treatment.
- Cardiology
- Molecular imaging tools are being used to detect atherosclerosis and cardiac ischemia.
- Potential for expanding theranostics into preventive cardiology.
- Neurology
- Early diagnosis and monitoring of neurodegenerative diseases such as Alzheimerβs and Parkinsonβs using biomarker-driven approaches.
- Personalized neurologic therapeutics are emerging with enhanced imaging.
- Autoimmune and Inflammatory Disorders
- Ongoing research into integrating diagnostic markers with targeted immunotherapies.
By End User
- Hospitals and Diagnostic Centers
- Largest market share due to the availability of advanced imaging infrastructure and patient volumes.
- Specialty Clinics
- Increasing adoption of targeted therapy and in-house diagnostics, particularly in oncology-focused facilities.
- Academic & Research Institutions
- Focus on development of novel biomarkers, radioisotopes, and drug delivery systems.
- Pharmaceutical & Biotechnology Companies
- Heavily investing in companion diagnostics and co-development strategies.
Regional Analysis
North America
North America is currently the largest theranostics market, led by the United States. The region benefits from well-established healthcare infrastructure, strong research capabilities, and the presence of major pharmaceutical and imaging technology companies. High adoption rates of precision medicine, government support for personalized therapies, and favorable reimbursement policies further enhance market growth.
Europe
Europe follows closely behind, with strong activity in countries such as Germany, France, and the U.K. The region is seeing increased adoption of companion diagnostics and radiopharmaceuticals, especially in oncology care. The European Medicines Agency (EMA) has taken progressive steps toward integrating companion diagnostics into drug approvals, which supports market expansion.
Asia-Pacific
The Asia-Pacific region is projected to witness the fastest growth through 2030. The increasing burden of cancer, improving healthcare infrastructure, growing awareness of advanced diagnostics, and rising investments in biotechnology are contributing to regional market expansion. Countries like China, Japan, and India are driving significant innovation in nuclear medicine and biologics.
Latin America and Middle East & Africa
These emerging markets are experiencing gradual adoption of theranostics, supported by improvements in healthcare systems and increasing awareness. The focus is currently on expanding diagnostic imaging capabilities and increasing access to radiopharmaceuticals.
Key Companies in the Market
The global theranostics market is characterized by the presence of both established and emerging players involved in the development of companion diagnostics, radiopharmaceuticals, and precision therapies. Leading companies include:
- GE Healthcare β A major player in diagnostic imaging and molecular imaging equipment.
- Siemens Healthineers β Known for integrated theranostic platforms and nuclear imaging technologies.
- Thermo Fisher Scientific β Active in molecular diagnostics and biomarker development.
- F. Hoffmann-La Roche Ltd β A leader in personalized oncology therapies and companion diagnostics.
- Bayer AG β Strong presence in radiopharmaceuticals and targeted therapy.
- Novartis AG β Pioneering theranostics in oncology through its Advanced Accelerator Applications division.
- Lantheus Holdings, Inc. β Specializes in radiopharmaceutical diagnostics and therapeutics.
- Danaher Corporation β Parent company of several diagnostic brands engaged in companion diagnostics.
- Cardinal Health β Involved in the manufacture and distribution of radiopharmaceuticals.
These companies are focusing on strategic partnerships, acquisitions, and R&D investments to strengthen their market position and expand theranostic capabilities globally.
Market Drivers and Trends
- Rising Prevalence of Cancer: Increasing global cancer incidence, particularly prostate and breast cancer, continues to drive demand for targeted diagnostic and therapeutic solutions.
- Shift Toward Personalized Medicine: The growing focus on individualized treatment regimens is fueling demand for companion diagnostics and biomarker-based drug development.
- Advancements in Molecular Imaging: The integration of PET, SPECT, and hybrid modalities such as PET/CT and PET/MRI enables early disease detection and precise monitoring.
- Radiotheranostics Gaining Traction: Combining radioactive diagnostics and therapy in one agent is gaining prominence, especially for metastatic and treatment-resistant tumors.
- Strategic Collaborations: Biotech and pharma companies are increasingly collaborating to co-develop therapies and diagnostics, accelerating time-to-market.
Challenges
- High Cost of Theranostic Procedures: The use of advanced technologies and isotopes makes theranostic solutions expensive, limiting accessibility in low-income settings.
- Limited Radiopharmaceutical Infrastructure: The need for specialized production, handling, and distribution facilities poses a significant barrier in several regions.
- Regulatory Complexities: Approvals for companion diagnostics and co-developed drugs can be complex and vary by region, slowing adoption.
Future Outlook
The theranostics market is entering a transformative phase. With advances in artificial intelligence, nanomedicine, and targeted drug delivery systems, the next generation of theranostics will be even more precise, efficient, and widely adopted. Emerging technologies such as CRISPR-based diagnostics, liquid biopsies, and AI-powered imaging analytics are set to redefine what is possible in personalized medicine.
In the coming years, theranostics is expected to become a central pillar in the standard of care across oncology and beyond, leading to more effective and customized patient treatment protocols worldwide.
More Trending Latest Reports By Polaris Market Research:
Diabetic Neuropathy Treatment Market
Algae Skincare Products Market